Literature DB >> 8257140

8-aminoquinolines effective against Pneumocystis carinii in vitro and in vivo.

S F Queener1, M S Bartlett, M Nasr, J W Smith.   

Abstract

The activities of 25 8-aminoquinolines were compared in tests assessing the ability of the compounds to inhibit the growth of Pneumocystis carinii in culture. Six compounds were effective at or below 0.03 microM: CDRI 80/53, NSC19894, NSC305805, NSC305812, WR182234, and primaquine. Four others were effective at between 0.2 and 0.03 microM: NSC305835, WR225448, WR238605, and WR242511. Fourteen drugs were also tested in a standard model of P. carinii pneumonia in rats at daily doses of 2 mg/kg of body weight in drinking water. CDRI 80/53, NSC305805, NSC305835, and WR225448 were extremely effective in the animal model. The effectiveness of WR238605, WR242511, and primaquine in the rat model has been reported elsewhere (M. S. Bartlett, S. F. Queener, R. R. Tidwell, W. K. Milhouse, J. D. Berman, W. Y. Ellis, and J. W. Smith, Antimicrob. Agents Chemother. 35:277-282, 1991). The length of the alkyl chain separating the nitrogens in the substituent at position 8 of the quinoline ring was a strong determinant of anti-P. carinii activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257140      PMCID: PMC192245          DOI: 10.1128/AAC.37.10.2166

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Clindamycin and primaquine as primary treatment for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS.

Authors:  J R Black; J Feinberg; R L Murphy; R J Fass; J Carey; F R Sattler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

2.  In vitro activities of acridone alkaloids against Pneumocystis carinii.

Authors:  S F Queener; H Fujioka; Y Nishiyama; H Furukawa; M S Bartlett; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

3.  Clindamycin with primaquine for Pneumocystis carinii pneumonia.

Authors:  E Toma; S Fournier; M Poisson; R Morisset; D Phaneuf; C Vega
Journal:  Lancet       Date:  1989-05-13       Impact factor: 79.321

4.  8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models.

Authors:  M S Bartlett; S F Queener; R R Tidwell; W K Milhous; J D Berman; W Y Ellis; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

5.  Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; J D Richardson; M M Durkin; M A Jay; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

6.  Pneumocystis carinii: improved models to study efficacy of drugs for treatment or prophylaxis of Pneumocystis pneumonia in the rat (Rattus spp.).

Authors:  M S Bartlett; J A Fishman; M M Durkin; S F Queener; J W Smith
Journal:  Exp Parasitol       Date:  1990-01       Impact factor: 2.011

7.  An enzyme-linked immunosorbent assay for enumeration of Pneumocystis carinii in vitro and in vivo.

Authors:  M M Durkin; M S Bartlett; S F Queener; M M Shaw; C H Lee; J W Smith
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

8.  Studies on the mechanisms of oxidation in the erythrocyte by metabolites of primaquine.

Authors:  K A Fletcher; P F Barton; J A Kelly
Journal:  Biochem Pharmacol       Date:  1988-07-01       Impact factor: 5.858

9.  Radical curative activity of a new 8-aminoquinoline derivative (CDRI 80/53) against Plasmodium cynomolgi B in monkeys.

Authors:  G P Dutta; S K Puri; A P Bhaduri; M Seth
Journal:  Am J Trop Med Hyg       Date:  1989-12       Impact factor: 2.345

10.  Metabolism of a potential 8-aminoquinoline antileishmanial drug in rat liver microsomes.

Authors:  A D Theoharides; H Chung; H Velazquez
Journal:  Biochem Pharmacol       Date:  1985-01-15       Impact factor: 5.858

View more
  9 in total

Review 1.  Treatment of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

2.  Activities and conformational fitting of 1,4-naphthoquinone derivatives and other cyclic 1,4-diones tested in vitro against Pneumocystis carinii.

Authors:  M D Ball; M S Bartlett; M Shaw; J W Smith; M Nasr; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

3.  Defective nitric oxide production by alveolar macrophages during Pneumocystis pneumonia.

Authors:  Mark E Lasbury; Chung-Ping Liao; Chadi A Hage; Pamela J Durant; Dennis Tschang; Shao-Hung Wang; Chen Zhang; Chao-Hung Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2010-06-17       Impact factor: 6.914

4.  Identification of a class of sulfonamides highly active against dihydropteroate synthase form Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium.

Authors:  L C Chio; L A Bolyard; M Nasr; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii.

Authors:  M S Bartlett; M Shaw; P Navaran; J W Smith; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

6.  Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase.

Authors:  I Ittarat; W Asawamahasakda; M S Bartlett; J W Smith; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

7.  Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate.

Authors:  N P Dhammika Nanayakkara; Arba L Ager; Marilyn S Bartlett; Vanessa Yardley; Simon L Croft; Ikhlas A Khan; James D McChesney; Larry A Walker
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

8.  Imidazoquines as antimalarial and antipneumocystis agents.

Authors:  Nuno Vale; Miguel Prudêncio; Catarina A Marques; Margaret S Collins; Jiri Gut; Fátima Nogueira; Joana Matos; Philip J Rosenthal; Melanie T Cushion; Virgílio E do Rosário; Maria M Mota; Rui Moreira; Paula Gomes
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

9.  Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia.

Authors:  Guang-Sheng Lei; Chen Zhang; Michelle K Zimmerman; Chao-Hung Lee
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.